
Delcath Systems (DCTH) Stock Forecast & Price Target
Delcath Systems (DCTH) Analyst Ratings
Bulls say
Delcath Systems Inc. is projected to experience revenue growth, with expectations of total revenues reaching $343 million by 2032, driven by increasing adoption of its Melphalan/HDS product and the expansion of treatment centers. Management's ongoing initiatives to enhance referrals and regional expansion are expected to support the sustained growth of Hepzato, particularly with the anticipated positive CHOPIN data poised to further boost utilization rates. Despite adjustments to revenue projections, the company's margins are anticipated to improve, contributing to a stronger bottom line, which reflects an optimistic outlook for its operational and financial performance.
Bears say
Delcath Systems Inc. has encountered significant obstacles affecting its financial performance, reporting a 15% quarter-over-quarter decline in total revenues for 3Q25, falling short of consensus estimates. The company's revised revenue guidance for full-year 2025 has been lowered to $83-$85 million, down from the previous expectation of $93-$96 million, which reflects challenges such as reduced new patient starts due to seasonality and competitive clinical trials. Additionally, a projected decrease in average revenue per kit attributable to the Medicaid National Drug Rebate Agreement further compounds the issue, indicating a troubling trend for the firm's financial outlook.
This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.
Delcath Systems (DCTH) Analyst Forecast & Price Prediction
Start investing in Delcath Systems (DCTH)
Order type
Buy in
Order amount
Est. shares
0 shares